• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.局部应用多激酶抑制剂莫替沙尼(AMG 706)对小鼠实验性脉络膜新生血管形成的抗血管生成作用
J Ocul Pharmacol Ther. 2015 Feb;31(1):25-31. doi: 10.1089/jop.2014.0023.
2
Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice.替沃扎尼布(一种口服 VEGF 受体酪氨酸激酶抑制剂)对实验性小鼠脉络膜新生血管的抗血管生成作用。
Exp Eye Res. 2013 Jul;112:125-33. doi: 10.1016/j.exer.2013.05.006. Epub 2013 May 20.
3
Anti-angiogenic effect of ALS-L1023, an extract of Melissa officinalis L., on experimental choroidal neovascularization in mice.唇形科植物蜜蜂花提取物ALS-L1023对小鼠实验性脉络膜新生血管的抗血管生成作用
Clin Exp Ophthalmol. 2016 Jan-Feb;44(1):43-51. doi: 10.1111/ceo.12583. Epub 2015 Oct 1.
4
Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib.通过全身给予多激酶抑制剂索拉非尼抑制小鼠脉络膜新生血管形成。
Br J Ophthalmol. 2009 Jul;93(7):958-63. doi: 10.1136/bjo.2008.149187. Epub 2008 Nov 21.
5
Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice.阿昔替尼,一种血管内皮生长因子受体酪氨酸激酶抑制剂,对小鼠激光诱导脉络膜新生血管的抗血管生成作用。
Curr Eye Res. 2013 Jan;38(1):119-27. doi: 10.3109/02713683.2012.727520. Epub 2012 Sep 27.
6
Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta.信号素3A可阻断由转化生长因子β诱导的病理性脉络膜新生血管形成。
Mol Vis. 2014 Sep 19;20:1258-70. eCollection 2014.
7
Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344.新型 CCR2 拮抗剂 INCB3344 抑制和消退小鼠脉络膜新生血管。
PLoS One. 2011;6(12):e28933. doi: 10.1371/journal.pone.0028933. Epub 2011 Dec 19.
8
Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.西地尼布(一种血管内皮生长因子受体酪氨酸激酶抑制剂)对脉络膜新生血管小鼠模型的作用。
Clin Exp Ophthalmol. 2013 Jan-Feb;41(1):63-72. doi: 10.1111/j.1442-9071.2012.02813.x. Epub 2012 Jul 2.
9
Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.阿帕替尼,一种血管内皮生长因子受体2抑制剂,可抑制小鼠病理性眼部新生血管形成。
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3592-3599. doi: 10.1167/iovs.17-21416.
10
Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.达沙替尼在氧诱导性视网膜病变和激光诱导性脉络膜新生血管小鼠模型中的抗血管生成作用。
Mol Vis. 2017 Nov 24;23:823-831. eCollection 2017.

引用本文的文献

1
Smoking aggravates neovascular age-related macular degeneration via Sema4D-PlexinB1 axis-mediated activation of pericytes.吸烟通过Sema4D-PlexinB1轴介导的周细胞激活加重新生血管性年龄相关性黄斑变性。
Nat Commun. 2025 Mar 22;16(1):2821. doi: 10.1038/s41467-025-58074-0.
2
Effect of topical motesanib in experimental corneal neovascularization model.局部莫特塞尼布对实验性角膜新生血管模型的影响。
Int Ophthalmol. 2023 Aug;43(8):2989-2997. doi: 10.1007/s10792-023-02685-3. Epub 2023 Mar 27.

本文引用的文献

1
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration.帕唑帕尼滴眼液:新生血管性年龄相关性黄斑变性的随机试验。
Br J Ophthalmol. 2014 Feb;98(2):172-8. doi: 10.1136/bjophthalmol-2013-303117. Epub 2013 Nov 13.
2
Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.评估一种新型储库递送策略,用于眼部新生血管疾病的 VEGF/PDGF RTK 抑制剂的非侵入性给药。
Invest Ophthalmol Vis Sci. 2013 Feb 27;54(2):1490-500. doi: 10.1167/iovs.12-10169.
3
Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.西地尼布(一种血管内皮生长因子受体酪氨酸激酶抑制剂)对脉络膜新生血管小鼠模型的作用。
Clin Exp Ophthalmol. 2013 Jan-Feb;41(1):63-72. doi: 10.1111/j.1442-9071.2012.02813.x. Epub 2012 Jul 2.
4
Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.帕唑帕尼(一种受体酪氨酸激酶抑制剂)对大鼠脉络膜新生血管的抗血管生成作用。
Eur J Pharmacol. 2011 Sep;666(1-3):12-8. doi: 10.1016/j.ejphar.2011.05.016. Epub 2011 May 20.
5
Motesanib and advanced NSCLC: experiences and expectations.莫特塞尼布与晚期非小细胞肺癌:经验与展望。
Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. doi: 10.1517/13543784.2011.579103. Epub 2011 May 2.
6
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
7
Immunohistochemical localization of low density lipoprotein receptor-related protein 1 and alpha(2)-Macroglobulin in retinal and choroidal tissue of proliferative retinopathies.免疫组化定位研究低密度脂蛋白受体相关蛋白 1 和α 2 -巨球蛋白在增殖性视网膜病变中的视网膜和脉络膜组织中的表达。
Exp Eye Res. 2010 Aug;91(2):264-72. doi: 10.1016/j.exer.2010.05.017. Epub 2010 Jun 1.
8
Effect of sorafenib on experimental choroidal neovascularization in the rat.索拉非尼对大鼠实验性脉络膜新生血管的作用。
Clin Exp Ophthalmol. 2010 Oct;38(7):718-26. doi: 10.1111/j.1442-9071.2010.02328.x. Epub 2010 Jul 9.
9
Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.新生血管性年龄相关性黄斑变性:眼内细胞因子和生长因子以及雷珠单抗治疗的影响
Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.
10
Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.甲磺酸伊马替尼治疗后进展的晚期胃肠道间质瘤日本患者中莫特沙尼的 II 期研究
Cancer Chemother Pharmacol. 2010 Apr;65(5):961-7. doi: 10.1007/s00280-009-1103-9. Epub 2009 Aug 19.

局部应用多激酶抑制剂莫替沙尼(AMG 706)对小鼠实验性脉络膜新生血管形成的抗血管生成作用

Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.

作者信息

Rho Chang Rae, Kang Seungbum, Park Ki Cheol, Yang Keum-Jin, Choi Hyunsu, Cho Won-Kyung

机构信息

1 Department of Ophthalmology and Visual Science, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea , Daejeon, South Korea .

出版信息

J Ocul Pharmacol Ther. 2015 Feb;31(1):25-31. doi: 10.1089/jop.2014.0023.

DOI:10.1089/jop.2014.0023
PMID:25255037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4286588/
Abstract

PURPOSE

To investigate the effect of topical motesanib, an inhibitor of receptor tyrosine kinase, on experimental choroidal neovascularization (CNV).

METHODS

CNV was induced in 46 nine-week-old male C57BL/6 mice using fundus laser photocoagulation. The right eye of each mouse was treated with motesanib eye drop (4 times daily) and the left eye with vehicle eye drop (4 times daily) for 14 days. To evaluate changes in the CNV lesions, fluorescein angiography, immunofluorescence staining with CD34, and histological examinations were performed 14 days after CNV induction. The expression of phosphorylated extracellular signal-regulated kinase (ERK1/2) in choroidal tissues was determined using western blot analysis to demonstrate the inhibitory effect of topically administered motesanib on intracellular signaling pathways involved in CNV development.

RESULTS

Fluorescein angiography showed that fluorescence leakage in eyes treated with topical motesanib was significantly less than in mice treated with vehicle (P=0.01). On immunofluorescence staining, the CD34-labeled area was smaller in topical motesanib-treated eyes (P<0.001). The expression level of phosphorylated ERK1/2 relative to that of total ERK1/2 decreased in eyes treated with topical motesanib compared with eyes treated with vehicle.

CONCLUSION

Topical motesanib significantly reduced laser-induced CNV in the experimental mouse model.

摘要

目的

研究受体酪氨酸激酶抑制剂莫特沙尼局部应用对实验性脉络膜新生血管(CNV)的影响。

方法

采用眼底激光光凝法在46只9周龄雄性C57BL/6小鼠中诱导CNV形成。每只小鼠的右眼用莫特沙尼滴眼液治疗(每日4次),左眼用赋形剂滴眼液治疗(每日4次),持续14天。在诱导CNV形成14天后,进行荧光素血管造影、CD34免疫荧光染色及组织学检查,以评估CNV病变的变化。采用蛋白质印迹分析测定脉络膜组织中磷酸化细胞外信号调节激酶(ERK1/2)的表达,以证明局部应用莫特沙尼对参与CNV形成的细胞内信号通路的抑制作用。

结果

荧光素血管造影显示,局部应用莫特沙尼治疗的眼睛荧光渗漏明显少于赋形剂治疗的小鼠(P = 0.01)。免疫荧光染色显示,局部应用莫特沙尼治疗的眼睛中CD34标记区域较小(P < 0.001)。与赋形剂治疗的眼睛相比,局部应用莫特沙尼治疗的眼睛中磷酸化ERK1/2相对于总ERK1/2的表达水平降低。

结论

在实验性小鼠模型中,局部应用莫特沙尼可显著减少激光诱导的CNV。